LabTwin Named a Finalist in 2019 Fierce Innovation Awards
The company was recognized in the Technology Innovation category, which acknowledges products and services that use technology solutions to serve the industry and promote innovations.
LabTwin, a voice- and artificial-intelligence-powered digital lab assistant, was named a finalist in Questex’s Fierce Innovation Awards-LifeSciences Edition in the Technology Innovation category, according to a Dec. 12, 2019 announcement. The Technology Innovation category recognizes products and services that use technology solutions to serve the industry and promote innovations, according to Questex’s 2019 innovation report.
The device, which reduces error rates and improves research efficiency with its voice-powered technology, was selected by a panel of judges from biotech and pharma companies, including Astellas, PPD Corporate Development & Strategy, Signant Health, Medidata Solutions, Accenture’s Global Applied Life Sciences Solutions Practice, Angelica Therapeutics, National Institute for Health Research’s Clinical Research Network, Biotech Research Group, Ostuaka Pharmaceuticals, AstraZeneca, and BrightInsight, a Flex Company.
“We are honored to be recognized as a finalist among other innovative tech companies for the life sciences community,” said Magdalena Paluch, co-founder and CEO of LabTwin, in a company press release. “LabTwin’s voice-powered assistant is used by hundreds of scientists in leading biopharma companies and academic institutions around the world, and we’re pleased to see that our product is making a difference in their research and discoveries.”
Later in December 2019, Questex announced that Cognoa, a pediatric behavioral health company in Palo Alto, CA, took home first place in the Technology Innovation category.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
